Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, ...

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an ...

ERD, is associated with measurable changes in concentrations of lipid mediators involved in inflammation and pain modulation, ...

A randomised placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who ...

Kashiv BioSciences, LLC, a fully-integrated biopharmaceutical company, announced that they have submitted a Biologics License ...

Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites –– Additionally, findings show that verekitug ...

Lyra Therapeutics (LYRA) announced the Company’s clinical plan and upcoming oral presentation of results from the positive Phase 3 ENLIGHTEN 2 ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

The FDA is expected to decide on treatments for acute myeloid leukemia, chronic rhinosinusitis with nasal polyps, lupus nephritis, pediatric myopia, and small-cell lung cancer.

POWELL – Veterinarians and animal care experts at the Columbus Zoo and Aquarium recently worked alongside specialists from ...

Interferon lambda concentrations in nasal lining fluid fell in or above the predicted therapeutic range with a nasally ...

Interferon-α nasal spray was safe and effective in reducing COVID-19 risk by 40% in patients with cancer, demonstrating its potential as an additional preventive strategy alongside vaccines and ...